Biosimilar medicines - Multistakeholder Event

As for the past years, the objective of the meeting was to raise awareness towards all and highlight the potential of biosimilars in improving affordability and access to medicines.

• Agenda
• Privacy statement

Video recordings and presentations

Patient keynote speech

• Sharing some reflections on living with a rheumatic and musculoskeletal disease
  Board of the Portuguese League Against Rheumatic Diseases (Liga 
  Portuguesa Contra as Doenças Reumáticas)

Ensuring biosimilar development and competition in Europe: where are we now?

Confirmed topics: IQVIA sharing the key findings of their yearly biosimilar competition report; EMA for a regulatory perspective on biosimilar development; DG COMP presenting the Competition Enforcement Report in the pharmaceutical sector (2018-2022)

• The impact of biosimilar competition in Europe
  IQVIA
• Regulatory perspective on the biosimilar pipeline and reflection on a tailored clinical approach to  biosimilar development
  European Medicines Agency 
• Update on biosimilar competition enforcement in the pharmaceutical sector (2018-2022)
  DG COMP, European Commission
• Clinical perspective on biosimilar use in the rheumatology field
  Diakonhjemmet Hospital Oslo

Video recording: Introduction and session 1

Updates on national biosimilar policies

Confirmed topics: keynote presentation on biosimilar use in the rheumatology field; as well as updates on different national biosimilar policies (including from Norway, Belgium and Portugal)

• Norway
  Sykehusinnkjop
• Belgium
  KU Leuven
• Portugal
  Infarmed

Video recording: Session 2

AUGMENT: an EU4Health biosimilar capacity-building project

The AUGMENT consortium, entailing the Austrian National Public Health Institute, the Polish Agency for HTA and Tariff System, Medical University of Sofia and NOVA University of Lisbon, will provide an introduction to the recently launched EU4Health project. The project aims to encourage biosimilar uptake through a comprehensive multistakeholder approach by generating evidence, enhancing knowledge, and building capacity. Participants are invited to attend the consortium's afternoon session, featuring engaging speakers and dynamic break-out discussions.

• Welcome and outline of the session
  DG SANTE, GÖG 
• Overview of the project and preliminary findings  
  AOTMIT, MUS, GÖG, NOVA

Video recording:

• AUGMENT session 1: Welcome and outline of the session
• AUGMENT session 2: Overview of the project and preliminary findings
• AUGMENT session 3: Invited commenters on the design of the project and expectations